Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1997;89:297-299
© 1997 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joura, E.
Right arrow Articles by Gitsch, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joura, E.
Right arrow Articles by Gitsch, G

Articles

Short-term effects of topical testosterone in vulvar lichen sclerosus

EA Joura, H Zeisler, D Bancher-Todesca, MO Sator, B Schneider, and G Gitsch

OBJECTIVE: To evaluate the systemic and therapeutic effect of topical testosterone treatment in vulvar lichen sclerosus. METHODS: This prospective clinical, single-arm study included ten postmenopausal women with vulvar lichen sclerosus. Testosterone propionate (0.04 g daily) was administered topically for 4 weeks. Serum androgens (testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate) were determined before and after 4 weeks of treatment, and vulvodynia was evaluated by a horizontal visual analogue scale. RESULTS: Serum levels of total testosterone increased in all patients (P < .01) and exceeded normal range in eight of ten women. Vulvodynia improved in nine of ten patients (paired t test: P < .01). Four of ten patients showed clinical signs of hyperandrogenism (enlargement of the clitoris, alterations of the voice, increase in libido) after 4 weeks of treatment. The only patient without subjective improvement had elevated basal serum androgen levels and showed clinical signs of hyperandrogenism before therapy. CONCLUSION: Topical testosterone is effective in normoandrogenic women with lichen sclerosus. Androgen status should be evaluated before treatment, and dosage should be individualized to avoid virilization and metabolic side effects. Because there is a marked systemic effect, clinical controls and a follow-up with evaluation of serum testosterone levels are recommended. Other steroids should be included in therapeutic decisions.


This article has been cited by other articles:


Home page
 Arch DermatolHome page
R. Kunstfeld, R. Kirnbauer, G. Stingl, and F. M. Karlhofer
Successful Treatment of Vulvar Lichen Sclerosus With Topical Tacrolimus
Arch Dermatol, July 1, 2003; 139(7): 850 - 852.
[Full Text] [PDF]

Home page
 Obstet GynecolHome page
P. HILLEMANNS, M. UNTCH, F. PROVE, R. BAUMGARTNER, M. HILLEMANNS, and M. KORELL
Photodynamic Therapy of Vulvar Lichen Sclerosus With 5-Aminolevulinic Acid
Obstet. Gynecol., January 1, 1999; 93(1): 71 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
P. D. Kohlberger, E. A. Joura, D. Bancher, G. Gitsch, G. Breitenecker, and D. G. Kieback
Evidence of Androgen Receptor Expression in Lichen Sclerosus: An Immunohistochemical Study
Reproductive Sciences, November 1, 1998; 5(6): 331 - 333.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American College of Obstetricians and Gynecologists.